SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Exelixis Announces Submission of Supplemental New Drug Application to US FDA for CABOMETYX in Combination With Opdivo for Advanced Renal Cell Carcinoma

Benzinga · 08/24/2020 12:08